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CC BY-NC-ND license (http://creativeSpinal tuberculosis (STB) is a common manifestation of extrapulmonary tuberculosis (TB). STB
accounts for around 2% of all cases of TB and around 15% of extrapulmonary TB cases. The
World Health Organization has proposed a global strategy and targets for TB prevention, care,
and control after 2015. Under this strategy, patients will receive standard care according to
the recommendations and guidelines after confirmation of STB diagnosis. However, current
recommendations and guidelines focus on disease and medication therapy management, and
recommendations for early detection or decision-making algorithms regarding STB are lacking.
In this review, we identified five key components for early diagnosis: (1) risk factors for STB; (2)
common symptoms/signs of STB; (3) significant neuroradiological findings of STB; (4) significant
laboratory findings of STB, including positive interferon-g release assays and nonpyogenic evi-
dence in initial laboratory data; and (5) significant clinical findings of STB. Individualized
consideration for each patient with STB is essential, and we hope that the algorithm esta-
blished in this review will provide a valuable tool for physicians who encounter cases of STB.
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826 C.-H. Chen et al.Introduction: tuberculosis, spinal
tuberculosis, and World Health Organization
strategies
Although tuberculosis (TB) is an ancient disease, it remains
a major global public health problem.1,2 After two decades
of progress toward TB elimination, annual decreases of 13
cases per 100,000 persons in Taiwan3 and at least 0.2 cases
per 100,000 persons in the USA4,5 have been reported.
Although pulmonary TB (PTB) is the most common form,
spinal TB (STB) is one of the oldest reported diseases in
humans and a common manifestation of extrapulmonary TB
(ETB).6 In 2011, there were an estimated 8.7 million cases
of TB globally, with 1.4 million TB-related deaths.7 Addi-
tionally, in Taiwan, there were 12,338 tuberculosis cases
(53 cases per 100,000 persons) and 626 TB-related deaths
(2.7 cases per 100,000 persons) in 2012.8 STB comprises
around 4% of all TB cases and around 15% of all ETB cases
within Taiwan.8
In response to global strategy and targets post 2015,
Taiwan Strategic and Technical Working Group for TB
performed costebenefit analyses and those analyses
were mainly divided into two parts. First, the preferred
utilization of a chest radiograph survey among high-risk
populations should be justified. Second, a model for the
endorsement of new diagnosis tools for TB patients and
latent TB infection patients should be established and
its practicability assessed.9 According to a World Health
Organization (WHO) report,8 the WHO post-2015
strategy proposal contains three components (Table
S1).10 Patients with a confirmed STB diagnosis receive
standard care according to those recommendations and
guidelines (Table S2). However, these recommendations
and guidelines focus on disease and medication therapy
management and lack significant evidence and
constructive recommendations for early detection as
well as decision-making algorithms regarding STB. Thus,
there is currently a lack of adequate evidence,
recommendations, and guidelines for the early diagnosis
of STB.
Effective vaccination is a mainstay of long-term policies
to combat and control the TB epidemic. The existing bacille
CalmetteeGue´rin vaccine has been shown to protect
against disseminated TB in young children11,12; however, its
protective effects against PTB are variable.12e14 Modified
TB vaccines include the Mycobacterium W15 and
recombinant bacille CalmetteeGue´rin vaccines16 and new
vaccines include the modified Vaccinia Ankara virus
expressing antigen 85A,17 adenovirus 35-vectored TB
vaccine candidate AERAS-402,18 H4:IC31,19 and M72/AS01
formulations.20,21 However, these new TB vaccines require
further evaluation and clinical trials to demonstrate their
efficiency and safety. Thus, early diagnosis and effective
treatment are the other essential long-term strategies for
controlling the TB epidemic. The first component of the
WHO post-2015 strategy is early diagnosis of TB,10 and a
rapid TB diagnosis is listed as the second main indication for
recommended diagnostic tests (Table S3).22 This review
focuses on early diagnosis of STB.Clinical aspects of STB
Natural clinical course
Spinal involvement usually results from the hematogenous
spread of Mycobacterium tuberculosis into the cancellous
bone tissue of the vertebral bodies. The primary infection
site comes from either a pulmonary focus or other extrap-
ulmonary foci, such as the lymph nodes.23e26 Predisposing
factors for STB include many categories, such as previous
TB infection, malnutrition, alcoholism, diabetes mellitus,
and human immunodeficiency virus infection.6,25,27
Clinical presentation
Delays in diagnosis of STB are common. In a report by
Sternbach,28 the average time from presentation to diag-
nosis is 1 year and 7 months. Typically, the onset of
symptoms is insidious, and disease progression is slow. The
duration of symptoms prior to diagnosis may range from 2
weeks to several years.6,25 To date, 2040 patients with STB
have been reported worldwide (Table S4). Male patients
comprise 53% of the STB-positive population, with a mean
age of 43.4 years (median, 43 years; Table S4). The clinical
presentation and findings of physical examinations depend
on the site and stage of the disease, presence of compli-
cations, and constitutional symptoms.6,25,29 The most
commonly reported symptoms are back pain (1438/2040,
70.4%), fever (667/2040, 32.7%), body weight loss (620/
2040, 30.3%), neurological abnormalities (315/2040,
30.1%), and night sweats (390/2040, 19.1%; Table S4).
Additionally, the thoracic spine is the most frequently
involved segment (Table S4). The complications after STB
included syringomyelia, permanent neurological deficits,
and spinal osseous defects.1,25 Paraplegia is the most
devastating complication of STB.6,25 The incidence of
neurological deficit varies from 23% to 76%.30
Clinical laboratory diagnosis
STB diagnosis is confirmed by typical clinical presentation
along with systemic constitutional manifestation, evidence
of past exposure to TB or concomitant visceral TB, and
neuroimaging modalities.6,25,31e33 Montoux skin tests and
hematological investigations, such as complete blood
count, erythrocyte sedimentation rate, enzyme-linked
immunosorbent assay, and polymerase chain reaction
(PCR), are also helpful in diagnosing STB.6,25,32,34 Bone
tissue or abscess samples stained for acid-fast bacilli,
mycobacterial organisms isolated from culture, and
computed tomography (CT)-guided or ultrasonography-
guided needle biopsy or surgical biopsy are also widely
used.6,25,35,36
Imaging diagnosis
Plain radiography is usually performed initially in patients
suspected to have STB, and plain radiograph images show
Early diagnosis of spinal tuberculosis 827bird-nest appearance characteristics of the aneurysmal
phenomenon.37 Magnetic resonance imaging (MRI) is the
modality of choice for imaging of STB. STB can be suggested
over pyogenic spondylodiscitis on the basis of several
characteristic MRI features. Typical MRI abnormalities
include spinal lesions that originate from the vertebral
endplate, involve the anterior vertebral body corner, show
evidence of subligamentous spread, exhibit multiple
vertebral bodies but preserved discs, and show extensive
paraspinal abscess formation, abscess calcification, and
vertebral destruction or vertebral body collapse.37 The
mean rates of abnormal findings in different imaging mo-
dalities are 15% in plain spinal radiography, 100% in MRI, and
100% in CT (Table S4). For radiolucent lesions to be visible
on plain radiographic images, there must be 30% bone
mineral loss.25,38,39 CT is more effective for defining the
shape and calcification of soft tissue abscesses than plain
radiography because CT provides much better visualization
of the bony details of irregular lytic lesions, sclerosis, disc
collapse, and disruption of bone circumference.6 However,
CT is less accurate for defining the epidural extension of the
disease and its effect on neural structures compared with
MRI. Hypointense T1-weighted and hyperintense T2-
weighted signal intensities, short tau inversion recovery
sequences, and administration of gadolinium with dieth-
ylene tri-amine penta-acetic acid are useful techniques for
differentiation of TB from pyogenic spondylitis .6,25,40,41
Treatment
Early diagnosis and appropriate empirical anti-TB agents
combined with surgery are associated with an excellent
prognosis.25,42e44 Surgical treatment is performed for
decompression, debridement, and fusion 25,43,45 and has
been used in w75.7% of diagnosed patients (Table S4), at
least 80% of whom have shown improvement (Table S4).
Physicians are not only familiar with the common clinical
features of STB but also have an in-depth understanding of
the disease; early diagnosis and effective treatment can
minimize sequelae and improve clinical outcomes. The
cornerstone of successful management of STB is early
detection and timely judicious medical interven-
tion.28,41,46,47 Since accurate and effective treatment and
early diagnosis are essential, but clinical evidence required
for early diagnosis of STB is still lacking. Hence, in this
review, we aimed to provide a summary of our under-
standing of STB, emphasizing early diagnostic evidence
from clinical clues, various modalities of medical imaging,
and recent advances in laboratory examinations, as well as
our clinical experiences with STB.
Summary of information regarding early
diagnosis of STB
Most patients with STB are not accurately diagnosed during
the initial stages of the disease due to delays from both
the patient and doctor48; such delays may result in sig-
nificant spinal damage.37 The golden standard method for
diagnosis of STB is positive M. tuberculosis culture from
tissue. Clinical judgment for STB has shown both poor
sensitivity and specificity. Moreover, the time to detectionof mycobacterial growth may be 4e6 weeks using tradi-
tional culture methods, including methods that utilize
LowensteineJensen medium; however, faster culture of
mycobacterial isolates has been reported, including
quantitative tissue culture on solid media, an automated
broth culture system from tissue specimens, quantitative
nucleic acid amplification of M. tuberculosis from tissue
samples, and measurement of TB antigen concentrations
in tissue samples. Nucleic acid amplification tests (NAATs)
provide a reliable method for increasing the specificity of
diagnosis (ruling in disease), but exhibit poor sensitivity
and cannot be used to rule out disease.49 Because we have
focused on early diagnosis, we have not provided a liter-
ature search of current culture methods in this review.
However, advanced clinical findings, laboratory methods,
and medical imaging modalities could be helpful for early
detection of STB. Notably, diagnosis of STB is a major
challenge for physicians because of the nonspecific, wide
spectrum of clinical presentations; this can result in
delayed diagnosis and risk of significant potential
morbidity and mortality due to the progression of the
disease and subsequent complications. Early diagnosis and
treatment is the key to avoiding this long-term disability.
Therefore, we searched the literature to summarize the
tools available for advanced detection and early diagnosis
(Table 1).A rapid biomarker-based nontissue-based test
In aneffort to developmoreaccurate tools for immunological
diagnosis of tuberculosis, two mycobacterial proteins, cul-
ture filtrate protein-10 and early secretory antigenic target-
6, have been evaluated.54,61,62 These immunodiagnostic
tests, the whole-blood interferon-g (IFN-g) enzyme-linked
immunosorbent assay (QuantiFERON-TB Gold; Cellestis Ltd,
Chadstone, Victoria, Australia) and the enzyme-linked
immunospot assay (T-SPOT.TB; Oxford Immunotec, Oxford,
UK), can quantitatively measure IFN-g production by lym-
phocytes specific to M. tuberculosis-specific immunodo-
minant antigens, which are encoded by the RD1 region of the
pathogen. Another commercially available IFN-g release
assay (IGRA), the QuantiFERON-TB Gold in-tube assay
(QFTGIT; Cellestis Ltd), is able to measure IFN-g production
specific to the immunodominant antigens TB7.7, early
secretory antigenic target-6, and culture filtrate protein-10.
A commercially available T-SPOT.TB assay, the ELISPOTassay
(i.e., T-SPOT. TB; Oxford Immunotec),63 has been devel-
oped. In addition, detection of lipoarabinomannan and A60
mycobacterial antigen have been reported.50,51 These
immunological diagnostic tools have been evaluated for
diagnosis of ETB, including STB, infections.
Based on a report by Kumar et al,46 in combination with
radiological criteria, bone scan, and enzyme-linked
immunosorbent assay, the QuantiFERON assay was pre-
dictive of tuberculosis in 90% of cases. A report by Yuan
et al53 showed that the ELISpot assay is a useful adjunct to
current tests for diagnosis of STB. Feng et al52 reported
that IGRA could function as a powerful immunodiagnostic
test to explore PTB and ETB, and T-SPOT.TB was shown to
be equally sensitive for determining PTB and ETB. Based
on the data of Cho et al,64 the T-SPOT.TB assay is more
Table 1 Summary of advanced information for early diagnosis of spinal tuberculosis.
Items Description Sensitivity/
specificity (%)
PPV/NPV
(%)
Comment and references
Gold standard
Mycobacterial
culture result
Direct test of tissue for
M. tuberculosis complex
/TB culture of tissue
NM NM For confirmation of STB
diagnosis24,25,32
Reference standard
Histopathological
result
Granulation
inflammation, caseous
necrosis
NM NM For suspected STB
diagnosis24,25,32
TB smear result TB smear of tissue NM NM For suspected STB diagnosis
24,25,32
Index tests
A rapid biomarker-based nontissue-based test
Enzyme-linked
immunosorbent
assay
Detection of A60
mycobacterial antigen
74/NM NM Although sensitivity is 63%
and specificity is 96%, it is
not a useful laboratory test
for diagnosis of active TB50
Selected panel of TB
antibodies
Detection of
lipoarabinomannan,
38-kDa antigen, and
16-kDa antigen
15.6/99.3 96.1/NM Could serve as an important
tool for diagnosis of TB,
especially ETB51
Immunodiagnostic
tests, the whole-
blood interferon-g
enzyme-linked
immunosorbent
assay
(QuantiFERON-TB
Gold; Cellestis Ltd,
Chadstone, Victoria,
Australia) and the
enzyme-linked
immunospot assay
(T-SPOT.TB; Oxford
Immunotec, Oxford,
UK)
Uses enzyme-linked
immunospot assays (T-
SPOT.TB; Oxford
Immunotec, Oxfordshire,
UK) to detect ETB
88.9/50.0 90.9 /NM The T-SPOT.TB test had a
higher sensitivity than the
QFT-GIT assay for diagnosing
ETB57
Uses blood T-SPOT.TB to
detect osteoarticular TB
100/55 62/NM The T-SPOT.TB was more
sensitive in patients with
chronic forms of ETB, such
as lymph node or
osteoarticular TB (93%, 95%
CI: 83e97%), than in
patients with acute forms of
ETB, such as TB meningitis
or miliary TB (79%, 95% CI:
66e87%, p Z 0.03)56
Uses QuantiFERON assay
to detect STB
84/95 90/NM ELISA, MRI of the spine, and
bone scanning findings
provide a reasonably certain
diagnosis in 90% of cases,
providing the grounds for
initiation of a trial to
determine the safety of
antituberculous
chemotherapy46
Enzyme-Linked
ImmunoSpot
(ELISpot) assay
Uses CFP10/ESAT6 fusion
protein as antigen to
detect spinal TB
specimens
82.7/87.2 89.6/79.1 Yuan et al showed that this
method has high sensitivity
and specificity and is an
effective technique for
auxiliary diagnosis of STB53
Measures the IFN-g
response to ESAT-6 and
CFP-10 in T cells in
samples of peripheral
blood mononuclear cells
of STB specimens
82.8/81.3 80.0/83.9 The ELISpot assay is a useful
adjunct to current tests for
diagnosis of atypical STB54
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Table 1 (continued )
Items Description Sensitivity/
specificity (%)
PPV/NPV
(%)
Comment and references
Uses IFN-g to detect STB
specimens
86.7/61.9 61.9/86.7 The ELISpot assay could
provide useful support in
diagnosing skeletal TB, and
STB could be excluded
based on a negative ELISpot
assays67
Rapid tissue-based tests
Polymerase chain
reaction
Uses PCR to detect STB
specimens
100/71.4 NM Although numbers in the
study by Van der Spoel van
Dijk et al. were too low to
effectively draw
statistically valid
conclusions, the importance
of the relevance of PCR for
rapid detection of low
numbers of acid-fast bacilli
and confirmation of
mycobacterial infection in
spinal biopsies has been
established.56
Analysis of
formaldehyde-fixed,
paraffin-embedded
tissue by PCR
94.7/83.3 94.7/83.3 Twenty-five formaldehyde-
fixed, paraffin-embedded
tissue blocks from vertebral
biopsy specimen materials
with presumptive diagnosis
of tuberculous spondylitis
were analyzed, with an
accuracy of 92%.57
Xpert MTB/RIF
assay, an automated
amplification
system
Uses Xpert MTB/RIF to
detect ETB
81.3/99.8 NM Positive likelihood ratios:
490.5; negative: 0.2.
Although the role of culture
remains central in the
microbiological diagnosis of
ETB, the sensitivity of Xpert
in rapidly diagnosing the
disease makes it a much
better choice compared
with smear microscopy72
Uses GeneXpert MTB/RIF
(Xpert) to detect ETB
77.3/98.2 NM Overall, the sensitivity and
specificity of the Xpert
assay are very high in
culture-positive specimens.
The high sensitivity is not
self-evident because only
small amounts of DNA are
expected in any
extrapulmonary clinical
sample71
Xpert MTB/RIF 81/99.6 NM The results of this study
suggest that the Xpert test
also shows good potential
for the diagnosis of ETB and
that its ease of use makes it
applicable for countries
where TB is endemic70
(continued on next page)
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Table 1 (continued )
Items Description Sensitivity/
specificity (%)
PPV/NPV
(%)
Comment and references
Advanced medical imaging
Fluorine-18-
fluorodeoxyglucose
positron emission
tomography/
computed
tomography imaging
Fluorine-18-
fluorodeoxyglucose
positron emission
tomography/computed
tomography imaging
90/NM NM The maximum SUVs of early-
phase PET/CT may be
complementary to MRI for
differentiating pyogenic and
tuberculous spondylitis and
reflecting the activity of
infectious spondylitis60
MRI Diagnosis based on
positive histopathology
results along with
supportive MRI
NM NM MRI findings showed
primarily shadowed areas
with features such as disc
destruction and thecal or
cord compression. MRI
scanning could be used for
early detection of spinal TB,
which can reduce disability
and deaths in patients37
Note: NM: not mentioned.
CFP10 Z culture filtrate protein 10; CT Z computed tomography; DNA Z deoxyribonucleic acid; ELISA Z enzyme-linked immunospot
assay; ESAT6 Z early secretory antigen target 6; ETB Z extrapulmonary tuberculosis; IFN-g Z Interferon-g; IGRA Z Interferon-g
release assays; NPV Z negative predictive value; MRI Z magnetic resonance imaging; PCR Z polymerase chain reaction; PET/CT Z
positron emission tomography/computed tomography; PPV Z positive predictive value; PTB Z pulmonary tuberculosis; QFT-IT Z
QuantiFERON-TB Gold In-Tube; TBZ tuberculosis; STBZ spinal tuberculosis; SUVZ standardized uptake value; TSTZ tuberculin skin
test.
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lymph node or osteoarticular TB (93%; 95% confidence
interval, 83e97%) than in patients with acute forms of
ETB, such as TB meningitis or miliary TB (79%; 95% confi-
dence interval, 66e87%; p Z 0.03). Additionally, studies
by Lai et al55 and Lai and Wang65 found that the T-SPOT.TB
assay was more sensitive than the QFTGIT for the diag-
nosis of ETB, particularly in culture-confirmed TB cases.
This suggests that the T-SPOT.TB assay may be a helpful
adjunct diagnostic tool in patients with suspected ETB.
However, Fan et al66 showed that IGRAs have limited value
as diagnostic tools to screen and rule out ETB, particularly
in low/middle-income countries. The immune status of
patients does not affect the diagnostic accuracy of IGRAs
for ETB. Rangaka et al67 showed that IGRAs do not have
high accuracy for the prediction of active TB, although use
of IGRAs in some populations may reduce the number of
patients considered for preventive treatment. Although
IGRA could be a powerful immunodiagnostic test for
evaluation of ETB, these new methods require further
investigations to determine their accuracy and safety in
different populations, particularly patients with STB.
Future studies are needed to address different epidemi-
ological and clinical settings, evaluate the performance of
common commercial assays in head-to-head comparisons,
and assess the role of adding more TB-specific antigens on
improving diagnostic sensitivity.
Rapid tissue-based tests
The promise of rapid diagnosis exists with the wide imple-
mentation of molecular platforms, such as PCR.56,57Turnaround times have been reported to be as short as 24
hours.68 Based on a report by Monni et al,69 the sensitivities
of culture and PCR are comparable (77% and 72%, respec-
tively). Some newer and more sensitive NAATs, including
the amplified M. tuberculosis direct test and Xpert MTB/RIF
(Xpert) assays, may enhance M. tuberculosis detection in
specimens. Xpert (Cepheid, Sunnyvale, CA, USA) is a fully
automated real-time heminested PCR system implementing
molecular beacon technology for the diagnosis of PTB
infection.
According to reports by Pai et al,70,71 commercial
NAATs may have a potential role in confirming the diag-
nosis of tuberculous meningitis and tuberculous pleuritis,
although their overall low sensitivity precludes their use
to rule out those types of ETB with certainty. Tortoli
et al72 evaluated the performance of the Xpert system in
many different extrapulmonary specimens in a country
with a low incidence of TB and found that, in comparison
with a reference standard consisting of combination of
culture and clinical diagnosis of TB, the Xpert system
exhibited an overall sensitivity and specificity of 81.3%
and 99.8%, respectively. The results of Hillemann et al’s59
study suggest that the Xpert test also shows good poten-
tial for the diagnosis of ETB and that its ease of use makes
it applicable for countries where TB is endemic. In addi-
tion, the sensitivity and specificity of the Xpert assay are
very high in culture-positive specimens. The high sensi-
tivity is not self-evident because only small amounts of
DNA are expected in any extrapulmonary clinical sam-
ple.58 Currently, there are also major clinical problems
with obtaining tissue specimens for diagnosis in most pa-
tients suspected of having STB.
Table 2 Early clinical presentation, laboratory results, and neuroradiological findings of patients with confirmed spinal
tuberculosis
Patient 1 2 3 4
Age (y)/sex 78/F 66/M 82/F 57/M
History of TB exposure þ þ þ þ
Initial laboratory data
White cell count (cells/mL) 4800 6200 5800 6800
ESR (mm/h) 45 45 38 68
CRP (mg/dL) 24.9 7.9 4.5 5.5
Albumin (g/dL) 4.2 3.2 3.5 3.6
Procalcitonin (ng/mL) 0.04 0.03 0.04 0.02
Positive IGRA þ þ þ þ
Initial neuroradiological findings
Originates from vertebral endplate þ þ þ þ
Involves the anterior vertebral body corner þ þ þ þ
Subligamentous spread þ þ þ þ
Multiple vertebral bodies involved & preserved disc þ þ þ þ
Extensive paraspinal abscess formation þ þ þ þ
Calcification of abscess þ þ þ þ
Vertebral destruction, vertebral body collapse (Gibbus deformity) þ þ þ þ
Definitive diagnosis
TB smear of tissue/MtbcDT of tissue/TB culture of tissue þ/þ/MTBC þ/þ/MTBC þ/þ/MTBC þ/þ/MTBC
Histopathological results GI GI, CN GI, CN GI, CN
No good response to traditional anti-bacterial regimens a þ þ þ þ
Patient delay (d)/doctor delay of ATA (d)/total delay (d) 60/5/65 30/5/35 32/5/37 60/3/63
ATA Z anti-TB agent; CN Z caseous necrosis; CRP Z C-reactive protein; ESR Z erythrocyte sedimentation rate; F Z female; GI Z
granulation inflammation; IGRA Z interferon- g release assays; M Z male; Mo Z month; MtbcDT Z Mycobacterium tuberculosis
complex direct test; TB Z tuberculosis .
a No good response to traditional antibacterial regimens meant that clinical signs and symptoms and the results of laboratory ex-
aminations did not improve after 3 days of administration of combination antibacterial regimens (anti-Staphylococcal agent with an anti-
Pseudomonal agent, such as oxacillin plus aminoglycosides).
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Lee et al60 reported MRI to be superior to positron emission
tomography and CT in differentiating between STB and
pyogenic spondylitis. MRI could be used for early detection
of STB, which could reduce the occurrence of disability and
death in these patients.37 MRI is the earliest diagnostic
modality for STB; however, confirmatory diagnosis can only
be made on the basis of biopsy or culture results.37,73Our experiences
A literature review revealed sparse research concerning
early diagnosis of STB; therefore, we summarized our
experience to analyze factors associated with early diag-
nosis of STB. Our experience included patients hospitalized
at Changhua Christian Hospital System, Changhua City,
Taiwan who were diagnosed with STB from January 1, 2010
to December 31, 2013. All adult patients diagnosed with
STB by all of the following methods were included: positive
vertebral osseous acid-fast bacilli; positive TB culture from
fine needle aspiration cytology specimens; and character-
istic pathologic findings. All patients diagnosed with STB
received standard anti-TB agents, according to the Taiwa-
nese guidelines for TB diagnosis and treatment.8
Five cases were diagnosed as having STB during the study
period. Four of these cases were confirmed to havemycobacterial infections with histopathological findings
confirming TB, while the other case was a non-TB myco-
bacterial infection. Thus, only four patients with confirmed
STB infections were enrolled in this study. The early clinical
presentations, laboratory results, and neuroradiological
findings of these patients are listed in Table 2. The neuro-
radiological findings of a patient with STB are shown in
Figure 1. All patients received standard anti-TB agents. Two
underwent surgical interventions for neurological deficits,
and all survived.
We noted five key components for early diagnosis: (1)
risk factors for STB; (2) common symptoms/signs of STB; (3)
significant neuroradiological findings of STB; (4) significant
laboratory findings of STB, including positive IGRA and
nonpyogenic evidence in initial laboratory data; and (5)
significant clinical findings of STB. STB has a wide variety of
manifestations. However, we identified five key indicators
for STB (Table 2), which were consistent with the obser-
vations in previous reports.74e78 According to a study in the
Netherlands by Jutte et al,48 there was a mean delay in the
diagnosis of nonspinal bone and joint TB of 35 weeks. In the
current study, the total delay duration ranged from 25 days
to 65 days. Early diagnosis of STB is important to prevent
negative outcomes.77 Wares et al77 described the nonspe-
cific radiological features of STB. However, we identified
seven key radiological findings observed in the lesions of
patients with STB (Table 2). Imaging is important for diag-
nosis and treatment of STB, and the diagnostic roles of
Figure 1 Neuroradiological findings of a patient with spinal tuberculosis. (A). Postgadolinium T1-weighted magnetic resonance
imaging with fat saturation, sagittal view, showing enhancement of the T9 and T10 vertebrae with apposing endplates erosion, and
enhanced soft tissue spreading along the anterior subligamentous space, from T7 to T12 level. Mild enhancement of the T8 inferior
and T11 superior vertebral bodies are also noted, but the T8/9 and T10/11 discs are preserved. (B). Postgadolinium T1-weighted
magnetic resonance imaging with fat saturation, axial (at T9e10 level) view, showing extensive paraspinal abscess (arrow). (C).
Computed tomography scan of the thoracic spine axial view showing calcification of the paraspinal abscess (arrow).
832 C.-H. Chen et al.various imaging modalities have been discussed previ-
ously.79 MRI and spiral CT are currently the most commonly
used imaging methods.
An algorithm for decision-making
Advanced clinical findings, laboratory methods, and
medical imaging could be helpful for early detection of
STB (Table 1). However, the availability and utility of
these methods are variable worldwide, including in
Taiwan. A successful experience to use an algorithmic
approach for patient management, and their results
enable early identifies candidates at high risk of TB
reactivation for anti-TB chemoprophylaxis.80 We have
developed a decision-making algorithm for the diagnosis
and management of STB based on our literature review
and our experience; we expect that this algorithm may be
useful at most institutes and facilities (Figure 2).1,74e79
Risk assessment for patients with suspicion of STB should
include the five key components. The risk assessment
elements are modified based on our experiences andprevious reports.74e76,78,81 MRI is one of the most useful
diagnostic methods for STB, often allowing an earlier
diagnosis than conventional methods. Rational orders for
MRI could reduce medical resource waste, according to
Taiwan’s National Health Insurance regulations. Patients
undergoing conservative treatment without surgery should
be monitored closely with serial clinical examinations (at
least weekly), ESR assessment (every 2e4 weeks), and MRI
or CT (depending on the clinical situation and level of risk
of the patient in order to assess abscess size and extent,
until resolution). Patients take anti-TB agents regularly
prior to meals under the directly observed treatment,
short course program.82 Optimized care involves risk
assessment of concurrent conditions, re-assessment of
follow-up conditions, and administration of appropriate
anti-TB agents with or without surgery.
Accurate diagnosis and adequate treatment of STB can
improve patient outcomes. Hence, the algorithm esta-
blished in this report (Figure 2) also includes decision-
making for the diagnosis and management of STB.1,74e79
Emergent surgical decompression should be initiated for
Figure 2 Algorithm for diagnosis and treatment of spinal tuberculosis. a Immediate investigations included complete medical
history, physical examinations, neurological examinations, laboratory examinations, and imaging examinations. b The grading
system score for spondylodiscitis is shown in Table S5. c Poor response was defined as a lack of reduction in clinical symptoms
and signs following administration of anti-TB agents. d Scoring for describing disability status based on functional disability
classification is shown in Table S6. CBC Z complete blood cell count; CRP Z C-reactive protein; CT Z computed tomography;
CXR Z chest X-ray; ESR Z erythrocyte sedimentation rate; F/U Z follow-up; FDC Z functional disability classification;
HIV Z human immunodeficiency virus; IGRA Z interferon-gamma release assay; LFT Z liver function test; MRI: magnetic
resonance imaging; PTB: pulmonary tuberculosis; RFT: renal function test; SD: spondylodiscitis; STB: spinal tuberculosis; WBC:
white blood cell count.
Early diagnosis of spinal tuberculosis 833patients with infection-induced moderate to severe
neurological compromise for the duration of anti-TB
agent treatment. The neurological status at the time of
presentation is a critical factor for treatment decision-
making and patient outcomes. If the imaging results
suggest STB, the decision for operative managementshould be based on risk assessment for the failure of
medical treatment according to the grading system for
spondylodiscitis (Table S5). Patients receiving medical
treatment alone may receive CT-guided drainage of the
target lesions. They should also be monitored and re-
assessed for signs of medical treatment failure. If these
834 C.-H. Chen et al.signs are detected, surgical decompression should be
promptly arranged.
Future studies
This review included a large number of studies; however,
continued research on this topic is necessary to define early
diagnosis of STB more accurately. Large-scale studies and
clinical trials are also required in order to develop and
validate more accurate modules, matrixes, or algorithms
for early diagnosis of STB based on advances in medical
technologies. In order to realize the incremental value of
combinations of tests, particularly for samples of tissue
specimens, it will be necessary to carry out large, pro-
spective, well-designed studies recruiting representative
samples of patients with STB. Longitudinal cohort studies to
confirm the positive predictive value of IGRAs for subse-
quent development of active TB and ETB (including STB)
should also be performed. M. tuberculosis transmission is
limited because of genetic evolution and deviation from
different geographic regions and ethnic populations in
Taiwan, and it remains to be investigated.83
Conclusion
In conclusion, TB is preventable and curable, and its
elimination would have widespread health, economic, and
social benefits. STB is a great challenge to physicians
because of the nonspecific, wide spectrum of clinical
presentations, which result in delayed diagnosis and risk of
significant morbidity and mortality. In this review, we have
summarized knowledge on early diagnosis of STB. A high
degree of clinical acumen and evaluation based on the five
indicators outlined in this review are important for STB
diagnosis and for starting treatment with anti-TB agents,
which is the current mainstay of treatment. In addition, MRI
is one of the most useful diagnostic methods for STB.
Individualized consideration of each patient with STB is
essential, and we hope that the algorithm developed in this
report (Figure 2) will be a valuable tool for physicians.
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